keyword
MENU ▼
Read by QxMD icon Read
search

Intravitreal implant

keyword
https://www.readbyqxmd.com/read/28935399/optical-coherence-tomography-biomarkers-as-functional-outcome-predictors-in-diabetic-macular-edema-treated-with-dexamethasone-implant
#1
Dinah Zur, Matias Iglicki, Catharina Busch, Alessandro Invernizzi, Miriana Mariussi, Anat Loewenstein
PURPOSE: Identification and characterization of patients with diabetic macular edema (DME) are important for individualizing treatment and optimizing outcome. We investigated optical coherence tomography (OCT) biomarkers for DME treated by intravitreal dexamethasone (DEX) implant. DESIGN: Multicenter, retrospective, observational cohort study. PARTICIPANTS: A total of 299 eyes from 284 patients treated with DEX implant for DME (naïve, n = 209; refractory, n = 90)...
September 18, 2017: Ophthalmology
https://www.readbyqxmd.com/read/28930489/an-overview-of-the-clinical-outcomes-of-the-fluocinolone-acetonide-190%C3%A2-%C3%A2%C2%B5g-intravitreal-implant-clinical-evidence-study-in-the-united-kingdom-ice-uk
#2
Tunde Peto
No abstract text is available yet for this article.
October 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28924446/use-of-intravitreal-dexamethasone-in-a-case-of-anterior-ischemic-optic-neuropathy
#3
Raffaele Nuzzi, Francesca Monteu
Nowadays there is no unique and well-established treatment for nonarteritic anterior ischemic optic neuropathy, despite being the main acute pathology that affects the optic nerve in the elderly population and often resulting in a significant loss of visual acuity. The effectiveness of oral steroids is still under debate in the international literature, although many studies show that patients treated with high doses of systemic corticosteroids have a significantly higher chance of improved visual acuity and visual fields...
May 2017: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/28924419/surprises-during-intravitreal-drug-delivery-a-report-of-three-cases
#4
Pradeep Venkatesh, Rohan Chawla, Bhavin Shah, Sat Pal Garg
We describe 3 cases with unusual events during and after intravitreal injection of dexamethasone intravitreal implants and bevacizumab. In case 1, delayed release of the safety stop of a dexamethasone intravitreal implant injector led to impaction and retinal break formation. Timely recognition and laser treatment prevented further retinal complications. In case 2, reinjection of a second dexamethasone intravitreal implant from the same site as the first injection was noted to dislodge the remnant of the previous implant from the vitreous base...
2017: Digital Journal of Ophthalmology: DJO
https://www.readbyqxmd.com/read/28922697/low-frequency-ranibizumab-versus-dexamethasone-implant-for-macular-oedema-secondary-to-branch-retinal-vein-occlusion
#5
Bora Yuksel, Omer Karti, Ozan Celik, Suleyman Gokhan Kerci, Tuncay Kusbeci
BACKGROUND: The aim was to make a real-world comparison of the efficacy of ranibizumab, dexamethasone and grid laser treatments in macular oedema due to branch retinal vein occlusion (BRVO). METHODS: Forty-four eyes of 44 consecutive patients with macular oedema secondary to BRVO were included. Treatment arms comprised standard care (StCARE, n = 15), intravitreal ranibizumab (RNB, n = 14) and dexamethasone implant (DEX, n = 15). No rescue laser was performed in DEX and RNB groups...
September 18, 2017: Clinical & Experimental Optometry: Journal of the Australian Optometrical Association
https://www.readbyqxmd.com/read/28918546/systemic-effects-of-repeated-intraocular-dexamethasone-intravitreal-implant-in-diabetic-patients-a-retrospective-study
#6
Alicia Valverde-Megías, Pilar Cifuentes-Canorea, Jorge Ruiz-Medrano, Pablo Peña-García, Alicia Megías-Fresno, Juan Donate-López, Julián García-Feijoo
INTRODUCTION: The objective of this study is to evaluate the influence of repeated intraocular dexamethasone implant (Ozurdex) injections on metabolic control in type 2 diabetic patients. METHODS: Retrospective study of 165 type 2 diabetic patients starting Ozurdex treatment who received no less than three consecutive injections. Glycated hemoglobin (HbA1c), serum creatinine, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides (TGs) were evaluated during 15 months of follow-up after Ozurdex treatment onset...
September 16, 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/28914687/prevention-of-macular-edema-after-cataract-surgery
#7
Laura H P Wielders, Jan S A G Schouten, Rudy M M A Nuijts
PURPOSE OF REVIEW: Although cataract surgery can effectively restore visual function in many patients with cataract, pseudophakic cystoid macular edema (PCME) remains an important cause of suboptimal visual acuity. The present review provides an overview of the current literature on the prevention and treatment of PCME. RECENT FINDINGS: Optimal prevention of PCME starts preoperatively with a personalized risk assessment. Diabetes mellitus, retinal vein occlusion, epiretinal membrane, macular hole, and uveitis are the most important risk factors for developing cystoid macular edema after cataract surgery...
September 12, 2017: Current Opinion in Ophthalmology
https://www.readbyqxmd.com/read/28900543/switching-to-aflibercept-in-diabetic-macular-edema-not-responding-to-ranibizumab-and-or-intravitreal-dexamethasone-implant
#8
Antoine Herbaut, Franck Fajnkuchen, Lise Qu-Knafo, Sylvia Nghiem-Buffet, Bahram Bodaghi, Audrey Giocanti-Auregan
PURPOSE: To assess short-term functional and anatomical outcomes of refractory diabetic macular edema (DME) following a switch from ranibizumab or dexamethasone to aflibercept. METHODS: We included retrospectively eyes with persistent DME after at least 3 ranibizumab and/or one dexamethasone implant intravitreal injections (IVI). The primary endpoint was the mean change in visual acuity (VA) at month 6 (M6) after switching. RESULTS: Twenty-five eyes were included...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/28884024/combined-phacoemulsification-and-intravitreal-dexamethasone-implant-ozurdex%C3%A2-in-diabetic-patients-with-coexisting-cataract-and-diabetic-macular-edema
#9
Claudio Furino, Francesco Boscia, Alfredo Niro, Ermete Giancipoli, Maria Oliva Grassi, Giuseppe D'amico Ricci, Francesco Blasetti, Michele Reibaldi, Giovanni Alessio
PURPOSE: To investigate the effectiveness and safety of combined phacoemulsification and dexamethasone intravitreal implant in patients with cataract and diabetic macular edema. METHODS: In this two-center, retrospective, single-group study, the charts of 16 consecutive patients who underwent combined phacoemulsification and intravitreal dexamethasone implant were retrospectively reviewed. These 16 patients, 7 men and 9 women, were observed at least 3 months of follow-up...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/28881152/determining-the-relative-cost-effectiveness-of-the-fluocinolone-acetonide-intravitreal-implant
#10
Simon Dixon
No abstract text is available yet for this article.
October 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28881150/patterns-of-retinal-thickness-prior-to-and-following-treatment-with-fluocinolone-acetonide-190%C3%A2-%C3%A2%C2%B5g-intravitreal-implant-for-diabetic-macular-edema
#11
Craig J Currie, Sarah E Holden, David R Owens
OBJECTIVES: To compare retinal thickness before and after treatment with the fluocinolone acetonide (FAc) 190 µg intravitreal implant in people with diabetic macular edema (DME) using data from the Iluvien Clinical Evidence study in the UK (ICE-UK). METHODS: For this retrospective cohort study, data on people attending any one of 13 participating ophthalmology departments and treated with FAc intravitreal implant between April 1, 2013 and April 15, 2015 were collected for 12 months prior to and at least 12 months after implantation...
October 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28881149/evaluation-of-the-clinical-effectiveness-in-routine-practice-of-fluocinolone-acetonide-190%C3%A2-%C3%A2%C2%B5g-intravitreal-implant-in-people-with-diabetic-macular-edema
#12
Sarah E Holden, Craig J Currie, David R Owens
OBJECTIVE: The aim of the Iluvien Clinical Evidence study in the UK (ICE-UK) was to assess the real-world effectiveness of fluocinolone acetonide (FAc) 190 µg intravitreal implant for the treatment of clinically significant chronic diabetic macular edema (DME) in routine clinical practice. METHODS: This retrospective study collected data from patient medical records in 13 ophthalmology centers for people with DME prescribed FAc intravitreal implant between April 1, 2013 and April 15, 2015...
October 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28881146/health-economic-evaluation-of-fluocinolone-acetonide-190%C3%A2-%C3%A2%C2%B5g-implant-in-people-with-diabetic-macular-edema
#13
Sarah E Holden, Craig J Currie, David R Owens
OBJECTIVES: To assess healthcare resource use and costs of treating people with clinically significant diabetic macular edema (DME) with fluocinolone acetonide (FAc) 190 µg intravitreal implant in routine clinical practice. METHODS: The retrospective Iluvien Clinical Evidence (ICE-UK) study collected data on people prescribed the FAc implant in any one of 13 ophthalmology centers between April 1, 2013 and April 15, 2015. Data were collected for 12 months before and after implantation...
October 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28881143/evaluation-of-the-clinical-effectiveness-of-fluocinolone-acetonide-190%C3%A2-%C3%A2%C2%B5g-intravitreal-implant-in-diabetic-macular-edema-a-comparison-between-study-and-fellow-eyes
#14
Craig J Currie, Sarah E Holden, Ellen Berni, David R Owens
OBJECTIVES: To compare visual and anatomical outcomes between eyes treated with fluocinolone acetonide (FAc) 190 µg intravitreal implant for clinically significant chronic diabetic macular edema (DME) and fellow eyes not treated with FAc implant using data from the Iluvien Clinical Evidence study in the UK (ICE-UK) study. METHODS: In this retrospective cohort study, data on people attending hospital eye services and treated with the FAc implant between April 1, 2013 and April 15, 2015 were collected...
October 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28872517/favorable-outcome-in-coccidioides-endophthalmitis-a-combined-medical-and-surgical-treatment-approach
#15
Jennifer J Ling, Derek J Bays, George R Thompson, Ala Moshiri, Mark J Mannis
PURPOSE: To describe a case of Coccidioides endophthalmitis that resulted in a favorable visual outcome after a combined medical and surgical approach. METHODS: A 33-year-old previously healthy woman was referred for evaluation of dyspnea and left-sided vision loss, which began 3 months before, after a trip to Nevada. She was found to have a pulmonary cavitary lesion and fluffy white material in the anterior chamber. An aqueous and vitreous paracentesis grew Coccidioides species...
August 31, 2017: Cornea
https://www.readbyqxmd.com/read/28865239/-principles-of-pharmacology-in-the-eye
#16
REVIEW
Sahar Awwad, Abeer H A Mohamed Ahmed, Garima Sharma, Jacob S Heng, Peng T Khaw, Steve Brocchini, Alastair Lockwood
The eye is a highly specialised organ that is subject to a huge range of pathology. Both local and systemic disease may affect different anatomical regions of the eye. The least invasive routes for ocular drug administration are topical (e.g. eyedrops) and systemic (e.g. tablets) formulations. Barriers that subserve as protection against pathogen entry also restrict drug permeation. Topically administered drugs often display limited bioavailability due to many physical and biochemical barriers including the pre-corneal tear film, the structure and biophysiologic properties of the cornea, the limited volume that can be accommodated by the cul-de-sac, the lacrimal drainage system and reflex tearing...
September 2, 2017: British Journal of Pharmacology
https://www.readbyqxmd.com/read/28860707/widening-use-of-dexamethasone-implant-for-the-treatment-of-macular-edema
#17
REVIEW
Vincenza Bonfiglio, Michele Reibaldi, Matteo Fallico, Andrea Russo, Alessandra Pizzo, Stefano Fichera, Carlo Rapisarda, Iacopo Macchi, Teresio Avitabile, Antonio Longo
Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious uveitis. The implant is formulated in a biodegradable copolymer to release the active ingredient within the vitreous chamber for up to 6 months after an intravitreal injection, allowing a prolonged interval of efficacy between injections with a good safety profile. Various other ocular pathologies with inflammatory etiopathogeneses associated with macular edema have been treated by DEX implant, including neovascular age-related macular degeneration, Irvine-Gass syndrome, vasoproliferative retinal tumors, retinal telangiectasia, Coats' disease, radiation maculopathy, retinitis pigmentosa, and macular edema secondary to scleral buckling and pars plana vitrectomy...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28853535/intravitreal-dexamethasone-implant-as-an-adjunct-weapon-for-severe-and-refractory-uveitis-in-beh%C3%A3-et-s-disease
#18
Claudia Fabiani, Giacomo Emmi, Giuseppe Lopalco, Lorenzo Vannozzi, Daniela Bacherini, Silvana Guerriero, Rossella Franceschini, Bruno Frediani, Florenzo Iannone, Gian Marco Tosi, Donato Rigante, Luca Cantarini
BACKGROUND: The evidence on the use of dexamethasone implants in the treatment of Behçet's disease (BD)-related uveitis is limited to a few cases. OBJECTIVES: To evaluate the efficacy of dexamethasone implants on ocular functional, morphological, and clinical parameters in BD patients with severe refractory uveitis. METHODS: Five eyes from five BD patients were enrolled. A single intravitreal dexamethasone injection was applied to each eye...
July 2017: Israel Medical Association Journal: IMAJ
https://www.readbyqxmd.com/read/28840855/comments-on-treatment-patterns-of-ranibizumab-intravitreal-injection-and-dexamethasone-intravitreal-implant-for-retinal-vein-occlusion-in-the-usa
#19
M A Williams, C Shute, S Wright
No abstract text is available yet for this article.
August 25, 2017: Eye
https://www.readbyqxmd.com/read/28839510/combined-intravitreal-dexamethasone-implant-and-micropulse-yellow-laser-for-treatment-of-anti-vegf-resistant-diabetic-macular-edema
#20
Ahmed Hosni Abd Elhamid
PURPOSE: To report the efficacy and safety of combined intravitreal dexamethasone implant and micropulse laser for anti-VEGF resistant diabetic macular edema. PATIENTS AND METHODS: Prospective, non-controlled study that was conducted for twenty eyes with center-involved diabetic macular edema not responding to anti-VEGF therapy. Ozurdex intravitreal implant was injected to all eyes with subsequent micropulse yellow laser one month after the injection. All eyes were followed up after one, three, four, six, nine and twelve months...
2017: Open Ophthalmology Journal
keyword
keyword
99632
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"